Oral paclitaxel for advanced GIST after other treatments fail
Part of Cancer, Digestive system clinical trials.
This trial tests an oral form of paclitaxel (a chemotherapy drug) for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to or caused side effects with imatinib, sunitinib, and regorafenib. It aims to see if this treatment can help when other options have run out.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old
- Your GIST has spread or is advanced and has a specific gene change (CD117, DOG-1, KIT, or PDGFRα)
- You’ve already tried imatinib, sunitinib, and regorafenib, and they stopped working or caused bad side effects
- You have a tumor sample that shows low levels of a protein called P-glycoprotein (less than 6 on a special test)
- You are well enough to be up and about (able to take care of yourself, out of bed more than half the day)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This trial tests how well temozolomide works and how safe it is for people with GIST (a type of stomach/intestine tumor) that is SDH-deficient and has no KIT or PDGFRα mutations. It may help by targeting tumor DNA repair weakness seen in this SDH-deficient subtype.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.